Remedium Lifecare Ltd.(BSE: 539561), a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has announced that its board approved raising of funds up to USD 25 Million by way of Foreign Currency Convertible Bonds (FCCBs), private placement, rights issue, preferential issue, Follow-on public offering (FPO), Qualified Institutions Placement (QIP), Global Depository Receipts (GDR), American Depository Receipts (ADR), or through any other permissible mode or a combination thereof, as may be considered appropriate, subject to shareholders’ approval as applicable and applicable regulatory/statutory approvals and requirements.
Earlier, the company entered into a strategic agreement with Angel Partners, Ltd., UK, effective July 29, 2024, to acquire technology for manufacturing lithium carbonate in India. The company also signed an annual Supply Agreement with Alfa Chemicals and Solvents Ltd., Turkey, effective the same date. Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at USD 20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. Remedium has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners, Ltd.
Remedium Lifecare Ltd., a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has bolstered its performance and presence within the pharmaceutical and healthcare domains by trading amino isophthalic acid, tellurium oxide, grignard reagent, iodine, selenium metal powder, trimethyl sulfoxonium iodide (TMSI). As a leading contract trader and brand owner of advanced intermediates and APIs, Remedium has shifted its paradigm into the trading of intermediates and APIs.
Reflecting the ethos of its Chairman, who believes in “working hard in silence and letting success make the noise,” Remedium is dedicated to upholding uncompromising quality
standards. Remedium has consistently raised the industry’s benchmarks through its
commitment to developing intermediates (KSMs & CRMs) and APIs that deliver unique value to patients and societies worldwide. Adapting swiftly to evolving demands, the company has emerged as one of the fastest-growing organizations in the global pharmaceutical industry.
“Quality is an ongoing process of building and sustaining relationships,” is the firm belief at
Remedium. Its unwavering commitment to quality products is backed by a highly qualified team of professionals, a cutting-edge infrastructure, and deep industry knowledge. Remedium strives to create mutually beneficial partnerships, adhering to high-quality standards as a matter of habit rather than chance.
Remedium is passionate about excellence and strives to deliver products with 0% defects,
earning trust as a reliable source for quality pharmaceutical and healthcare products. It is
committed to a rigorous product development process that involves constant modernization
and adherence to international standards, since it has one of the largest portfolios of intermediates and active pharmaceutical ingredients (APIs), responsible for the therapeutic
effects of various medicines.